Literature DB >> 11027423

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy.

J A Kohler1, J Imeson, C Ellershaw, S O Lie.   

Abstract

One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11027423      PMCID： PMC2363577          DOI： 10.1054/bjoc.2000.1425

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Response of neuroblastoma to retinoic acid in vitro and in vivo.

Authors:  C P Reynolds; D J Kane; P A Einhorn; K K Matthay; V L Crouse; J R Wilbur; S B Shurin; R C Seeger
Journal:  Prog Clin Biol Res       Date:  1991

2.  13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group.

Authors:  J Z Finklestein; M D Krailo; C Lenarsky; S Ladisch; G K Blair; C P Reynolds; A L Sitarz; G D Hammond
Journal:  Med Pediatr Oncol       Date:  1992

3.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

4.  Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.

Authors:  J G Villablanca; A A Khan; V I Avramis; R C Seeger; K K Matthay; N K Ramsay; C P Reynolds
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

5.  9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.

Authors:  W H Miller; A Jakubowski; W P Tong; V A Miller; J R Rigas; F Benedetti; G M Gill; J A Truglia; E Ulm; M Shirley
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

Review 6.  Retinoids as preventive and therapeutic anticancer agents (Part I).

Authors:  S M Lippman; J F Kessler; F L Meyskens
Journal:  Cancer Treat Rep       Date:  1987-04

7.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma.

Authors:  C J Thiele; C P Reynolds; M A Israel
Journal:  Nature       Date:  1985 Jan 31-Feb 6       Impact factor: 49.962

9.  Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.

Authors:  K H Kraemer; J J DiGiovanna; A N Moshell; R E Tarone; G L Peck
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640
View more
  13 in total

Review 1.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

Review 2.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Frank Berthold
Journal:  Cochrane Database Syst Rev       Date:  2017-08-25

3.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

4.  Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Authors:  Stacey M Frumm; Zi Peng Fan; Kenneth N Ross; Jeremy R Duvall; Supriya Gupta; Lynn VerPlank; Byung-Chul Suh; Edward Holson; Florence F Wagner; William B Smith; Ronald M Paranal; Christopher F Bassil; Jun Qi; Giovanni Roti; Andrew L Kung; James E Bradner; Nicola Tolliday; Kimberly Stegmaier
Journal:  Chem Biol       Date:  2013-05-23

5.  Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

Authors:  Katherine K Matthay
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

6.  Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Authors:  Gareth J Veal; Julie Errington; Sophie E Rowbotham; Nicola A Illingworth; Ghada Malik; Michael Cole; Ann K Daly; Andrew D J Pearson; Alan V Boddy
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

Review 7.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat.

Authors:  F Ponthan; P Kogner; P Bjellerup; L Klevenvall; M Hassan
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

9.  High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center.

Authors:  Jung Min Suh; Keon Hee Yoo; Ki Woong Sung; Ju Youn Kim; Eun Joo Cho; Hong Hoe Koo; Suk Koo Lee; Jhingook Kim; Do Hoon Lim; Yeon Lim Suh; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

10.  Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients.

Authors:  Juan C Gutierrez; Anne C Fischer; Juan E Sola; Eduardo A Perez; Leonidas G Koniaris
Journal:  Pediatr Surg Int       Date:  2007-05-03       Impact factor: 2.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.